COX-2 Gastrointestinal Safety Profile Questioned By BMJ Study
This article was originally published in The Pink Sheet Daily
British Medical Journal researchers were concerned to find increased risk for rofecoxib since lower GI risk “was one of the main justifications for use.”
You may also be interested in...
Payors and consumers overspent nearly $6 bil. over three years by choosing celecoxib and meloxicam over traditional, less-expensive therapies, according to Journal of Managed Care Pharmacy.
Compliance consultants warn that certain dietary supplement good manufacturing practices violations are inspection "showstoppers" and will draw agency enforcement